The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma.

Lu, Zhihao; Yang, Silu; Luo, Xuerui; Shi, Yang; Lee, Jong-Seok; Deva, Sanjeev; Liu, Tianshu; Chao, Yee; Zhang, Yun; Huang, Ruiqi; Xu, Yaling; Shen, Zhirong; Shen, Lin

Lu, Zhihao; Yang, Silu; Luo, Xuerui; Shi, Yang; Lee, Jong-Seok; Deva, Sanjeev; Liu, Tianshu; Chao, Yee; Zhang, Yun; Huang, Ruiqi; Xu, Yaling; Shen, Zhirong; Shen, Lin.

Afiliação

Lu Z; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China.
Yang S; BeiGene (Beijing) Co., Ltd., Beijing, China.
Luo X; BeiGene (Shanghai) Co., Ltd., Shanghai, China.
Shi Y; BeiGene (Beijing) Co., Ltd., Beijing, China.
Lee JS; Seoul National University Bundang Hospital, Seoul, South Korea.
Deva S; Auckland City Hospital, Auckland, New Zealand.
Liu T; Zhongshan Hospital Fudan University, Shanghai, China.
Chao Y; Taipei Veterans General Hospital, Taipei City, Taiwan.
Zhang Y; BeiGene (Beijing) Co., Ltd., Beijing, China.
Huang R; BeiGene (Shanghai) Co., Ltd., Shanghai, China.
Xu Y; BeiGene (Shanghai) Co., Ltd., Shanghai, China.
Shen Z; BeiGene (Beijing) Co., Ltd., Beijing, China.
Shen L; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China. shenlin@bjmu.edu.cn.

Gastric Cancer ; 25(5): 943-955, 2022 09.

Article em En | MEDLINE | ID: mdl-35778636

Assuntos

Adenocarcinoma; Neoplasias Pulmonares; Neoplasias Gástricas; Adenocarcinoma/tratamento farmacológico; Adenocarcinoma/genética; Anticorpos Monoclonais Humanizados; Antígeno B7-H1; Biomarcadores Tumorais/genética; Ensaios Clínicos Fase I como Assunto; Ensaios Clínicos Fase II como Assunto; Neoplasias Esofágicas; Junção Esofagogástrica/patologia; Humanos; Neoplasias Pulmonares/tratamento farmacológico; Mutação; Fosfatidilinositol 3-Quinases/genética; Receptor de Morte Celular Programada 1/genética; Neoplasias Gástricas/tratamento farmacológico; Neoplasias Gástricas/genética

Palavras-chave

Gastroesophageal adenocarcinoma; Hyperamplification; Immuno-oncology; PD-(L)1 inhibitor; PD-L1

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Adenocarcinoma / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google